Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor
Ronald P. DeMatteo(University of Pennsylvania), Kouros Owzar(Duke University), Martin D. McCarter(University of Colorado Cancer Center), Jeffrey A. Norton(Stanford University), George D. Demetri(Dana-Farber Cancer Institute), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Violetta Kolesnikova(Memorial Sloan Kettering Cancer Center), Karla V. Ballman(Mayo Clinic in Arizona), Murray F. Brennan(Memorial Sloan Kettering Cancer Center), Margaret von Mehren(Temple University Health System), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Peter W. T. Pisters(The University of Texas MD Anderson Cancer Center), Christopher L. Corless(Oregon Health & Science University)
Cited by 174
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k